Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 21

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 21
---
, strategic partnerships,
joint ventures, restructurings, divestitures, business combinations, and investments. Any such transaction may require us to incur non-recurring
or other charges, may increase our near- and long-term expenditures, and may pose significant integration challenges or disrupt our management
or business, which could adversely affect our operations and financial results. For example, these transactions entail numerous potential
operational and financial risks, including:

    ●
    exposure
    to unknown liabilities;

    ●
    disruption
    of our business and diversion of our management’s time and attention in order to develop acquired products, clinical assets,
    or technologies;

    ●
    incurrence
    of substantial debt or dilutive issuances of equity securities to pay for acquisitions;

    ●
    substantial
    acquisition and integration costs;

    ●
    write-downs
    of assets or impairment charges;

    ●
    increased
    amortization expenses;

    ●
    difficulty
    and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;

    ●
    impairment
    of relationships with key suppliers, partners, or customers of any acquired businesses due to changes in management and ownership;
    and

    ●
    inability
    to retain our key employees or those of any acquired businesses.

Accordingly,
there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transaction
that we do complete could harm our business, financial condition, operating results, and prospects.

42

Manufacturing
and supply of the APIs and other substances and materials used in our clinical assets is a complex and technically challenging undertaking,
and there is potential for failure at many points in the manufacturing, testing, quality assurance, and distribution supply chain, as
well as the potential for latent defects after products have been manufactured and distributed.

Manufacturing
and supply of APIs, other substances, and materials and finished drug products is technically challenging. Changes beyond our direct
control can impact the quality, volume, price, and successful delivery of our clinical assets and can impede, delay, limit, or prevent
the successful development and commercialization of our clinical assets. Mistakes and mishandling are not uncommon and can affect successful
production and supply. Some of these risks include:

    ●
    failure
    of our manufacturers to follow cGMP or GACP requirements or mishandling of product while in production or in preparation for transit;

    ●